Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy
Key result
Non-anticoagulation linked to ~72% greater stroke and vascular risk versus warfarin in HCM with AF.
- P<0.05
- n=900
Population
900 patients with hypertrophic cardiomyopathy from four regional cohorts
Comparison
Patients with atrial fibrillation receiving warfarin vs non-anticoagulated patients
Design
Community-based cohort study without significant tertiary referral bias
Follow-up
7 +/- 7 years
Authors
Discussion
Loading...
Member takes
Implication
Cohort study reveals stroke frequency and thromboembolic outcomes in hypertrophic cardiomyopathy, highlighting atrial fibrillation as a primary driver.
Key Points
- To characterize the clinical presentation, incidence, risk factors, and long-term outcomes of stroke in individuals diagnosed with hypertrophic cardiomyopathy.
- Evaluated a longitudinal cohort of 900 consecutive patients diagnosed with hypertrophic cardiomyopathy.
- Tracked incident thromboembolic complications, cerebrovascular events, and cardiac arrhythmias over long-term follow-up.
- Cerebrovascular stroke and systemic thromboembolic events occurred predominantly in patients who developed atrial fibrillation.
- Thromboembolic events caused substantial morbidity, leading to permanent neurological disability and mortality among affected patients.
Study Design
Type
Cohort (n=900)
Multicenter
Yes
PICO
P
Population
900 consecutive patients with hypertrophic cardiomyopathy from four regional cohorts, followed for a mean of 7 years.
E
Exposure / Comparator
Non-anticoagulation vs Warfarin
O
Primary Outcome
Stroke and other peripheral vascular events, p=< 0.05
Main Result
Absolute Event Rate: 31% vs 18%
p-value: p=< 0.05
Cite This Study
Maron et al. (2002) conducted a cohort in Hypertrophic cardiomyopathy (n=900). Non-anticoagulation vs. Warfarin was evaluated on Stroke and other peripheral vascular events (p=< 0.05). In hypertrophic cardiomyopathy with atrial fibrillation, non-anticoagulation was associated with a higher incidence of stroke and peripheral vascular events compared to warfarin (31% vs 18%; p<0.05).